SciELO - Scientific Electronic Library Online

 
vol.30 número2Estudio Comparativo entre Soluciones Conservadoras con y sin Formol en Placenta HumanaVariantes Anatómicas de los Forámenes Oval y Espinoso en Cráneos Humanos índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

International Journal of Morphology

versión On-line ISSN 0717-9502

Resumen

CAVENAGHI, F. M et al. Protease Inhibitor and Metabolic Alteration. Int. J. Morphol. [online]. 2012, vol.30, n.2, pp. 439-444. ISSN 0717-9502.  http://dx.doi.org/10.4067/S0717-95022012000200014.

Protease inhibitors (PIs), part of HAART (Highly Active Antiretroviral Therap) are selective, competitive inhibitors of protease, a crucial enzyme to viral maturation, infection and replication. A lipodystrophic syndrome has been reported in individuals treated with HAART, and associated to hyperglycemia, hypercholesterolemia, hypertrigliceridemia, hyperlipidemia, hypertension and hypreinsulinemia. The HAART-associated metabolic abnormalities were first associated with protease inhibitors, Ritonavir mostly, but the mechamisns that underlie these metabolic alterations are to date, not completely understood. Since PIs are candidate to be the drug of choice for other diseases treatment, such as the Hepatitis C, malaria and some types of cancer, it seems to be important to clarify the metabolic alterations associated to PIs. Wistar rats were treated twice a week with 30mg/kg Ritonavir for 4 and 8 weeks. Total cholesterol, HDL, LDL, VLDL, triglycerides and glycemic levels were measured by the end of each period of time selected. To avoid confunding effects of food intake, the animals were fasted 16 hours before. Our results showed rapid increase in serum triglycerides, total cholesterol, LDL-C and glycemic levels. No significant differences were observed for HDL-C or VLDL serum levels. Our study addresses the importance to observe the possible family history of dyslipidemia or diabetes, and control any other cardiovascular and diabetes risk factors when using protease inhibitors.

Palabras clave : Protease inhibitors; Dyslipidemia; Metabolic disorders.

        · resumen en Español     · texto en Inglés     · pdf en Inglés